Man wins nearly $400,000 on sports bet, only to have it all canceled by BetMGM
Woman dies after jumping out 3rd floor window during home invasion and shooting
Ben & Jerry's alleges parent company Unilever removed its CEO over social activism
Legal showdown as Justice Department resists judge's demand for more details on deportation flights
France to distribute ‘survival manual’ to prepare households for emergencies – including armed conflict
Boeing CFO flags worries over tariffs impact on parts availability
Google hit with 2 charges under landmark EU rules, risks fines
US crude stocks rise, gasoline and distillate inventories fall - EIA
Penn Badgley just gave us a crossover for the ages
The world's tallest teen, 7-foot-9 Olivier Rioux, is working to expand his NIL-earning power
By Susan Heavey and Ahmed Aboulenein
WASHINGTON (Reuters) - Senior Biden administration officials met with RSV vaccine makers this week to underscore the need for manufacturers such as Sanofi and AstraZeneca to urgently meet demand as winter approaches, the White House said on Tuesday.
At a meeting at the White House on Monday, officials and manufacturers also agreed to plan now to meet next year's demand for the vaccines targeting respiratory syncytial virus, which generally causes mild, cold-like symptoms but can develop into severe illness in infants and older adults.
"Monday's meeting follows numerous in-person and virtual meetings to seek ways manufacturers can make more RSV immunizations available for infants," the White House said in a statement.
Representatives for Sanofi and AstraZeneca did not immediately respond to a request for comment.
Separately, the U.S. Centers for Disease Control and Prevention said it had expedited the release of more than 77,000 additional doses of Sanofi and AstraZeneca's RSV drug Beyfortus which was approved earlier this year to prevent the disease in infants and toddlers.
RSV cases in the U.S. began a sharp upward trend in the middle of October and were at the highest level since January last winter with 4,952 cases detected through testing in the week ended Nov. 4, according to the CDC website.
(Reporting by Susan Heavey and Ahmed Aboulenein; Additional reporting by Mike Erman; Editing by Katharine Jackson and Nick Zieminski)
